Ensysce Biosciences (NASDAQ:ENSC) Issues Earnings Results

Ensysce Biosciences (NASDAQ:ENSC) released its quarterly earnings results on Tuesday. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.37, Zacks reports. The company had revenue of $3.42 million for the quarter, compared to analysts’ expectations of $0.25 million. Ensysce Biosciences had a negative net margin of 179.26% and a negative return on equity of 559.68%.

Ensysce Biosciences Price Performance

ENSC stock traded down $0.07 during midday trading on Thursday, hitting $0.64. The stock had a trading volume of 1,501,519 shares, compared to its average volume of 8,561,608. The company’s 50-day moving average price is $0.36 and its 200 day moving average price is $0.45. The firm has a market cap of $5.61 million, a PE ratio of -0.39 and a beta of 0.63. Ensysce Biosciences has a 12-month low of $0.14 and a 12-month high of $2.06.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.